February 15, 2020 – Utrecht, the Netherlands

Researchers at MILabs B.V. have succeeded at imaging the popular Zirconium-89 (89Zr) isotope in small animals of human disease at very high resolutions (<0.75 mm). 89Zr as used for Positron Emission Tomography (PET) has great appeal to immune-oncology researchers because it is a nearly ideal radioisotope for PET imaging with immunoconjugates, as it possesses a multi-day physical half-life that is compatible with the in vivo pharmacokinetics of antibodies. Unfortunately, its positron-rage of 1.3-3.9mm and background of high energy prompt gamma’s causes non-isotropic blurring and haziness in the PET images of small laboratory animals making quantification and mapping of tumor heterogeneity in mouse oncology models virtually impossible. Quantification of tracer uptake and accurate assessment of tumor heterogeneity is considered by cancer researchers as essential for the development of effective therapies.

By using information of prompt photon emissions and advanced modelling of high energy photon transport during image reconstruction, the researchers at MILabs have succeeded at dramatically improving the three-dimensional imaging precision over conventional PET. Moreover, since MILabs’ PET systems can image multiple isotopes, 89Zr-immunoPET therapies and 18F-FDG cancer staging can now be performed simultaneously in the same animal at high-resolution to augment cancer therapy research.

Prof. Frederik Beekman, CEO/CSO MILabs states: “We are exited that we have been able to complete our mission of making imaging clear for difficult PET isotopes by eliminating the positron range blurring effect from small animal imaging for three important PET isotopes: 82Rb for cardiac imaging, 124I for e.g. oncolytic virus therapy imaging and now 89Zr for immunotherapy imaging.”

About MILabs B.V.:

This fast-growing Dutch company has a history of providing a continuum of innovations to expand the applications of preclinical imaging. With its latest adaptive platform, MILabs has succeeded at commercializing a scalable imaging platform, able to accommodate PET, SPECT, Optical and X-ray CT imaging. MILabs has built a strong brand based on its mission of “Making Imaging Clear”. With ultra-high-resolution and multiparametric imaging complemented by theranostic capabilities, it provides efficient translational systems for both diagnostic and therapy applications. For more information, visit:  www.milabs.com or contact MILabs at [email protected]


Share on social media
Share on facebook
Share on twitter
Share on linkedin
Share on email

Miltenyi Biotec strengthens its research capabilities for cell analysis and preclinical imaging by acquiring a MILabs’ premium Optical/CT imaging system

  Utrecht and Bergisch Gladbach, September 9, 2020 Miltenyi Biotec B.V. & Co. KG, a …

Read More →

MILabs announced the co-winners of the MILabs Image of the Year Award

September 4, 2020, Utrecht, The Netherlands Each year, at the occasion of the Annual Congress …

Read More →

Bayer AS installs top-of-the-line MILabs VECTor PET/SPECT/CT to advance its targeted alpha therapy programs

August 27, 2020, Oslo-Norway and Utrecht-The Netherlands Bayer AS has installed a state-of-the-art MILabs VECTor …

Read More →

Spotlight on Prof. Marion de Jong – Erasmus MC Rotterdam

Spotlight on Prof. Marion de Jong – Erasmus MC Rotterdam On the frontline of fighting …

Read More →

The University of Southampton enters the field of Correlative In-Vivo Imaging by acquiring MILabs 3D/4D Optical/CT

May 12, 2020, Southampton, UK – Utrecht, the Netherlands The Faculty of Medicine, University of …

Read More →

MILabs remotely installs from the Netherlands new E-Class PET/SPECT/CT at Osaka University of Pharmaceutical Sciences

Osaka, Japan and Utrecht, the Netherlands May 4th, 2020 In a world with COVID-19 travel …

Read More →

University of Torino (UNITO) acquires an advanced MILabs molecular imaging system

The University of Torino (UNITO) acquires advanced MILabs molecular imaging system for the design of …

Read More →

Truman VA acquires VECTor preclinical imaging system featuring exclusive multimodal synergy capabilities.

Columbia, Missouri, USA and Utrecht, the Netherlands April 9th, 2020 Harry S. Truman Memorial Veterans’ …

Read More →

Cyprus-based EPOS-Iasis acquires MILabs innovative Optical/CT system

Aimed at achieving a paradigm shift in Oncology research by imaging and quantifying fluorescent signals …

Read More →

MILabs enhances micro-CT for Coronavirus (COVID-19) research.

March 19, 2020 – Utrecht, the Netherlands Based on recent scientific research, diagnostic X-ray CT …

Read More →

The Julius Wolf Institute at the Charité installs mission-critical MILabs microCT for in-vivo studies of musculoskeletal regeneration

25 February 2020 – Berlin-Germany and Utrecht, Netherlands, The Julius Wolff Institute for Biomechanics and …

Read More →

MILabs realizes a breakthrough in preclinical oncology imaging by eliminating the positron range effect of 89Zr-immunoPET

February 15, 2020 – Utrecht, the Netherlands Researchers at MILabs B.V. have succeeded at imaging …

Read More →
Scroll to Top